Gil Ben-menachem
Vice President
Business Development
Kitov Pharmaceuticals Ltd
Israel
Biography
Dr. Gil Ben-Menachem has served as Kitov's Vice President Business Development since 2016. Dr. Ben-Menachem has over 15 years of experience in the pharmaceutical, biotechnology, and venture capital industries. He most recently served as Head of Innovative Products at Dexcel Pharma, Israel’s second-largest pharmaceutical company. Dr. Ben-Menachem previously served as Director of Business Development at Teva Pharmaceutical Industries, where he was responsible for business development efforts in connection with partnering and acquisition deals for late-stage innovative drug candidates. Previous to that, he served as CEO of OphthaliX, a company that developed drugs in the ophthalmology space, and Director of Business Development at Paramount Biosciences, a New York-based merchant bank and biotechnology venture capital firm. Dr. Ben-Menachem received his PhD from the Hebrew University, and MBA from the University of Maryland. He concluded his postdoctoral training in immunology and microbiology at the NIH. Dr. Gil Ben-Menachem has served as Kitov's Vice President Business Development since 2016. Dr. Ben-Menachem has over 15 years of experience in the pharmaceutical, biotechnology, and venture capital industries. He most recently served as Head of Innovative Products at Dexcel Pharma, Israel’s second-largest pharmaceutical company. Dr. Ben-Menachem previously served as Director of Business Development at Teva Pharmaceutical Industries, where he was responsible for business development efforts in connection with partnering and acquisition deals for late-stage innovative drug candidates. Previous to that, he served as CEO of OphthaliX, a company that developed drugs in the ophthalmology space, and Director of Business Development at Paramount Biosciences, a New York-based merchant bank and biotechnology venture capital firm. Dr. Ben-Menachem received his PhD from the Hebrew University, and MBA from the University of Maryland. He concluded his postdoctoral training in immunology and microbiology at the NIH.
Research Interest
Business Development
